<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287222</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2005-13</org_study_id>
    <nct_id>NCT00287222</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma</brief_title>
  <official_title>Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy endpoint will be the proportion of subjects that remain free of
      progression at the 27th week following the onset of treatment. Secondary objectives include
      the subject's time in weeks from treatment onset to documented disease progression as
      assessed by the RECIST criteria, response rate, median and overall survival, safety and
      tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study to assess the proportion of subjects that remain progression-free by
      the 27th week following the onset of treatment and to assess the efficacy of the combination
      of Bevacizumab and Erlotinib in prolonging time to progression in subjects with inoperable
      and metastatic hepatocellular carcinoma. Subjects will be treated with a combination of
      rhuMAb VEGF (Bevacizumab), in combination with Erlotinib and TTP will be assessed as per
      RECIST criteria. The disease will be evaluated at base line and every 9 weeks with CT
      scan/MRI and AFP levels. Subjects will be kept on the study till disease progression (as
      defined by RECIST criteria) or death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Remained Free of Progression at the 27th Week.</measure>
    <time_frame>27 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1 - Bevacizumab/Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with bevacizumab and erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/KG I.V. every 21 days</description>
    <arm_group_label>1 - Bevacizumab/Erlotinib</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg orally every day</description>
    <arm_group_label>1 - Bevacizumab/Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects should have histologically or cytologically confirmed diagnosis of
             hepatocellular carcinoma, regardless of biopsy site.

          -  Subjects with a liver mass and markedly elevated AFP (&gt;500ng/mL) are eligible.

          -  Subjects should not be on the liver transplantation schedule

          -  Subjects can have prior therapy with sorafenib (nexavar) only if the therapy was
             stopped due to toxicity or allergic reaction soon after starting. Subjects must have
             been treated for less than two weeks to be eligible.

          -  Radiation therapy for palliation to the areas outside the site of tumor used for
             measurements is permitted. If a subject has received radiation therapy to the liver,
             the subject id eligible if there is a new lesion or if the prior lesion has increased
             in size.

          -  Subjects who have recovered from prior surgical procedure

          -  Performance status of ECOG 0-2

          -  Measurable or evaluable disease

          -  Be declared unresectable or not suitable candidates for surgery

          -  Adequate organ functions

          -  Serum bilirubin &lt;3 mg/dl, AST &lt;5x ULN, ALT &lt;5XULN

          -  Serum albumin &gt;2.5 g/dl

          -  Serum creatinine &lt; 2.0 mg/dl

          -  ANC &gt;1200 MM3

          -  Platelet count &gt;75,000/ml

          -  PT/INR &lt; 1.5 X ULN

          -  Life expectancy of &gt;3 months

          -  Subjects should be able to sign informed consent and be agreeing to comply with
             therapy and follow up.

          -  Negative pregnancy test in women with childbearing potential, within one week prior to
             initiation of treatment.

          -  Fertile men and women must agree to use adequate contraception prior to study entry,
             for the duration of study participation, and for at least 1 week after therapy.

          -  Age &gt;/= 18 years. The agents Bevacizumab and Erlotinib have not been studied in
             pediatric subjects, thus the doses to be used in this study cannot be assumed to be
             safe in children.

        Exclusion Criteria:

          -  Surgically resectable disease

          -  Subjects with active bacterial infections

          -  Subjects with brain metastases

          -  Pregnant women (positive pregnancy test) or lactating

          -  No other malignancy is allowed except for adequately treated basal cell (or squamous
             cell) skin cancer, in situ cervical cancer or other cancer for which the subject has
             been disease-free for five years.

          -  Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sjogren's
             syndrome) or congenital abnormality (e.g. Fuch's dystrophy).

          -  Current, recent (within 4 weeks of the first infusion of the study), or planned
             participation in an experimental drug study other than a Genentech-sponsored
             Bevacizumab/Erlotinib cancer study

          -  Hepatic encephelopathy (as per treating physician's evaluation)

          -  Uncontrolled blood Pressure &gt;150/100 mmHg

          -  Unstable angina

          -  NYHA grade II or greater congestive heart failure

          -  History or myocardial infraction within 6 months

          -  History of stroke within 6 months

          -  Clinically significant peripheral vascular disease (clinically significant venous or
             arterial thrombotic disease).

          -  Evidence of bleeding diathesis or coagulopathy

          -  Urine protein: creatinine ratio &gt;1.0 at screening

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Inability to comply with study and/or follow-up procedures

          -  Gastrointestinal disease resulting in an inability to take oral medication or a
             requirement for intravenous hyperalimentation.

          -  History of significant gastrointestinal bleeding requiring procedural intervention
             (e.g. variceal banding, TIPS procedure, arterial embolization, topical coagulation
             therapy) within six months prior to study Day 0.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, or anticipation of need for major surgical procedure during the course
             of the study.

          -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
             prior to Day 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rangaswamy Govindarajan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <results_first_submitted>March 22, 2011</results_first_submitted>
  <results_first_submitted_qc>June 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2011</results_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rangaswamy Govindarajan</name_title>
    <organization>UAMS</organization>
  </responsible_party>
  <keyword>Inoperable and Metastatic Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period was from 7/08/2005 to 12/17/2008. Recruitment occurred at the University of Arkansas for Medical Sciences medical oncology clinic and Kansas University Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab and Erlotinib</title>
          <description>Subjects will be treated with bevacizumab and erlotinib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab and Erlotinib</title>
          <description>Subjects will be treated with bevacizumab and erlotinib</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Remained Free of Progression at the 27th Week.</title>
        <time_frame>27 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Erlotinib</title>
            <description>Subjects will be treated with bevacizumab and erlotinib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Remained Free of Progression at the 27th Week.</title>
          <population>Per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Estimating the percentage of participants that remain free of disease progression at 27 weeks from the onset of treatment, and testing that proportion against a null-hypothesis proportion of 0.04 using the one-sided exact binomial test at 5% alpha, based upon historical data from the literature.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>one-sided exact binomial test</method>
            <param_type>percentage progression free at 27 weeks</param_type>
            <param_value>28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10</ci_lower_limit>
            <ci_upper_limit>53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab and Erlotinib</title>
          <description>Subjects will be treated with bevacizumab and erlotinib</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two subjects withdrew consent.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sandy Annis</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>5016868274</phone>
      <email>amannis@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

